Strategic Wealth Investment Group LLC Acquires 275 Shares of STERIS plc (NYSE:STE)

Strategic Wealth Investment Group LLC lifted its stake in STERIS plc (NYSE:STE) by 6.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,667 shares of the medical equipment provider’s stock after acquiring an additional 275 shares during the quarter. Strategic Wealth Investment Group LLC’s holdings in STERIS were worth $1,100,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. J.Safra Asset Management Corp grew its stake in shares of STERIS by 77.9% in the first quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 53 shares in the last quarter. Central Pacific Bank Trust Division acquired a new stake in STERIS in the 3rd quarter valued at about $28,000. Quent Capital LLC grew its holdings in STERIS by 112.7% during the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 71 shares during the period. Headlands Technologies LLC acquired a new position in STERIS during the first quarter worth approximately $36,000. Finally, Versant Capital Management Inc raised its stake in STERIS by 2,262.5% in the second quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 181 shares during the period. 94.69% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

STE has been the subject of several research analyst reports. KeyCorp lifted their target price on STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 3rd. Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Thursday, August 8th. StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Finally, Stephens reissued an “overweight” rating and issued a $260.00 price target on shares of STERIS in a report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, STERIS has a consensus rating of “Moderate Buy” and a consensus target price of $253.00.

STERIS Stock Performance

NYSE STE opened at $224.01 on Tuesday. The firm has a 50-day moving average price of $234.76 and a two-hundred day moving average price of $226.46. STERIS plc has a 12-month low of $195.47 and a 12-month high of $248.24. The company has a market capitalization of $22.09 billion, a P/E ratio of 55.59 and a beta of 0.84. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35.

STERIS (NYSE:STE) last issued its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.16. The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.27 billion. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The firm’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.00 earnings per share. Analysts anticipate that STERIS plc will post 9.06 earnings per share for the current year.

STERIS Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Thursday, September 5th were paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date was Thursday, September 5th. This is an increase from STERIS’s previous quarterly dividend of $0.52. STERIS’s payout ratio is 56.58%.

Insider Buying and Selling

In other news, CFO Michael J. Tokich sold 23,332 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the transaction, the chief financial officer now directly owns 42,930 shares in the company, valued at approximately $10,603,710. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other STERIS news, Director Christopher S. Holland sold 473 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the transaction, the director now owns 582 shares of the company’s stock, valued at approximately $139,493.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the transaction, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at $10,603,710. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by company insiders.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.